A new study shows that lowering MSH3, a key DNA repair protein, with antisense oligonucleotide (ASO) therapy can stop CAG repeat expansions in HD patient-derived brain cells. This could be a promising way to slow symptom onset and progression.
Avoid the hype: HDBuzz has Ten Golden Rules for navigating news stories or press releases about Huntington's disease.
Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this update mean for the HD community and this trial?
A recent paper links CAG repeat expansion with widespread RNA changes, especially in brain cells vulnerable to HD. “Knocking out” certain DNA repair genes that go awry in HD can have positive effects on features of HD in mice.
New research suggests the adult brain can be convinced to grow new neurons to replace those lost in Huntington’s disease. The SUPER exciting part? These cells don’t just grow—they seem to connect and function, like puzzle pieces clicking into place.
New research shines a light on an often-overlooked side of Huntington’s disease—psychosis. Understanding the impact of psychosis on daily life and progression of other HD symptoms could be key to providing better care and support.
Hope is in full bloom at HDBuzz! We’re growing—doubling article output, expanding our team, & keeping Huntington’s disease families informed. Now, we need YOUR help to stay independent & strong. Donate today & fuel free, trusted HD research news!
With so much science going on in the Huntington’s disease space, we’re bringing you a monthly recap from March 2025 to cover all the biggest HD science news and research we covered this month. Enjoy!
A new CRISPR-based technology, called RIDE, is a leap forward for this trail-blazing technology. With the precision of a scalpel sharp enough to rewrite the very code of life, researchers have used it with the hope of treating Huntington’s disease.